Bio-Techne Corp (TECH) To Go Ex-Dividend on November 13th

Bio-Techne Corp (NASDAQ:TECH) announced a quarterly dividend on Tuesday, November 3rd. Stockholders of record on Friday, November 13th will be given a dividend of $0.08 per share by the biotechnology company on Monday, November 23rd. This represents a $0.32 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 13th. This is a 87.7% decrease from Bio-Techne’s previous quarterly dividend of $0.65.

Bio-Techne has a dividend payout ratio of 15.4% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Bio-Techne to earn $1.97 per share next year, which means the company should continue to be able to cover its $0.32 annual dividend with an expected future payout ratio of 16.2%.

Bio-Techne Stock Up 0.1%

Shares of NASDAQ:TECH opened at $72.73 on Thursday. The company has a market cap of $11.42 billion, a price-to-earnings ratio of 63.24, a PEG ratio of 5.27 and a beta of 1.29. Bio-Techne has a one year low of $43.19 and a one year high of $72.83. The firm has a fifty day moving average price of $72.47 and a two-hundred day moving average price of $63.35. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.55 and a quick ratio of 3.35.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.52. The company had revenue of $321.19 million during the quarter, compared to the consensus estimate of $314.63 million. Bio-Techne had a net margin of 14.97% and a return on equity of 13.23%. The firm’s revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.53 EPS. Analysts anticipate that Bio-Techne will post 1.75 EPS for the current fiscal year.

Bio-Techne Company Profile

Bio-Techne Corporation is a life sciences company that develops and supplies research and diagnostic products for biotechnology, pharmaceutical, academic, clinical and other laboratory customers. The company supports biological research, drug discovery and development, and diagnostic testing through a portfolio of reagents, instruments and analytical technologies.

Its products include proteins, antibodies, immunoassays, flow cytometry reagents, molecular biology tools and cell culture materials.